मूलभूत आँकड़े
| LEI | 5493000T6CXTND40YH31 |
| CIK | 1023024 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ANI Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 8, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PHARMACEUTICA |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 8, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| August 8, 2025 |
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance •Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basis •Total Rare Disease quarterly net revenues of $104.0 million, which includes: ◦Purified Cortrophin® Gel net reven |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 29, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| July 23, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME) Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients with DME Results presented by Michael A. S |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 23, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 23, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| July 23, 2025 |
NEW DAY Clinical Trial Results July 23, 2025 1 Disclaimers 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Act, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| July 11, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ANI Pharmaceuticals, Inc. |
|
| July 11, 2025 |
Amended and Restated ANI Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan. Exhibit 10.1 AMENDED AND RESTATED ANI PHARMACEUTICALS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN The following constitute the provisions of the Amended and Restated ANI Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan. 1.Purpose; Effectiveness. (a)The purpose of the Plan is to provide employees of the Company and its Designated Parents or Subsidiaries with an opportunity to purchase Common Sto |
|
| July 11, 2025 |
As filed with the Securities and Exchange Commission on July 11, 2025 As filed with the Securities and Exchange Commission on July 11, 2025 Registration No. |
|
| July 11, 2025 |
As filed with the Securities and Exchange Commission on July 11, 2025 As filed with the Securities and Exchange Commission on July 11, 2025 Registration No. |
|
| July 11, 2025 |
Exhibit 10.1 ANI PHARMACEUTICALS, INC. AMENDED AND RESTATED 2022 STOCK INCENTIVE PLAN (Amended on May 22, 2025) 1.Purpose of Plan. The purpose of the ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan (this “Plan”) is to advance the interests of ANI Pharmaceuticals, Inc. (the “Company”) and its stockholders by enabling the Company and its Subsidiaries to attract and retain qu |
|
| July 11, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ANI Pharmaceuticals, Inc. |
|
| June 4, 2025 |
a250604anipjefferiesconf © 2025 ANI Pharmaceuticals, Inc. 1 Corporate Presentation June 2025 © 2025 ANI Pharmaceuticals, Inc. 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about our expectations, beliefs, plans, objectives |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 4, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission F |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 22, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission F |
|
| May 23, 2025 |
Exhibit 3.1 Certificate of Amendment of the Restated Certificate of Incorporation of ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of the Corporation is ANI Pharmaceuticals, Inc. SECOND: Article IV of the Restated Certifi |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 20, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission F |
|
| May 20, 2025 |
© 2025 ANI Pharmaceuticals, Inc. 1 Corporate Presentation May 2025 © 2025 ANI Pharmaceuticals, Inc. 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about our expectations, beliefs, plans, objectives, assumptions or future ev |
|
| May 9, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PHARMACEUTIC |
|
| May 9, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 9, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 9, 2025 |
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance EX-99.1 2 anip-20250509xexx991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance •Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4% •Total Rare Disease quarterly net revenues of $69.0 million, which includes: ◦Purified Cortrophin® Gel net revenues of $5 |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 6, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 6, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to §240. |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Additional Materials o Soliciting Material Pursuant to §240. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to §240. |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 18, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| March 18, 2025 |
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ® ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ® BAUDETTE, Minn. |
|
| March 14, 2025 |
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label •ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic macular edema (DME) •ANI plans to begin marketing ILUVIEN in the U. |
|
| March 14, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 14, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| March 11, 2025 |
© 2025 ANI Pharmaceuticals, Inc. 1 Leerink Partners Global Healthcare Conference March 11, 2025 © 2025 ANI Pharmaceuticals, Inc. 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about our expectations, beliefs, plans, objecti |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 11, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 28, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commiss |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-31812 ANI PHARMACEUTICALS, |
|
| February 28, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance •Generated record quarterly net revenues of $190.6 million, representing year-over-year growth of 44.8% •Total Rare Disease quarterly net revenue of $87.0 million, which includes: ◦Record quarterly net revenue for Purified Cortrophin® Gel of $59.4 milli |
|
| February 28, 2025 |
Exhibit 21 ANI PHARMACEUTICALS, INC. The following is a list of subsidiaries of ANI Pharmaceuticals, Inc., omitting subsidiaries which, considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary, as of December 31, 2024: Name Jurisdiction of Incorporation or Organization Alimera Sciences Europe Limited Ireland Alimera Sciences, Inc. Delaware Alimera Sciences |
|
| February 28, 2025 |
Exhibit 19.1 ANI PHARMACEUTICALS, INC. INSIDER TRADING AND CONFIDENTIALITY NOTICE (as adopted on May 7, 2023) ANI Pharmaceuticals, Inc. (“ANI”) has adopted the attached restatement and expansion of its existing policies and procedures prohibiting directors, officers, employees, consultants and their immediate family members from (1) trading in the securities of ANI, and in certain cases, the secur |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 5, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commissi |
|
| February 5, 2025 |
© 2025 ANI Pharmaceuticals, Inc. 1 Guggenheim SMID Cap Biotech Conference February 5, 2025 © 2025 ANI Pharmaceuticals, Inc. 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about our expectations, beliefs, plans, objectives, |
|
| January 21, 2025 |
EX-99.1 2 tm253994d1ex-1.htm EXHIBIT I EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.0001 per share, of ANI Pharmaceuticals, Inc. will be filed on behalf of e |
|
| January 13, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook •For full year 2024, the Company expects total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be at or above the guidance ranges provided on November 8, 2024 •Rare Disease Segment performed in line with expectations, with P |
|
| January 13, 2025 |
© 2025 ANI Pharmaceuticals, Inc. 1 J.P. Morgan Healthcare Conference January 14, 2025 © 2025 ANI Pharmaceuticals, Inc. 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about our expectations, beliefs, plans, objectives, assum |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commissi |
|
| November 20, 2024 |
exhibit991investordeck11 © 2024 ANI Pharmaceuticals, Inc. 1 Jefferies Healthcare Conference November 20, 2024 © 2024 ANI Pharmaceuticals, Inc. 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about our expectations, beliefs, |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 20, 2024 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commiss |
|
| November 13, 2024 |
ANIP / ANI Pharmaceuticals, Inc. / Rubric Capital Management LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427812d2sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ANI Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00182C103 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropri |
|
| November 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PHARMACE |
|
| November 8, 2024 |
ANI Pharmaceuticals, Inc Amended and Restated 2022 Stock Incentive Plan Notice of Restric Exhibit 10.5 ANI PHARMACEUTICALS, INC. AMENDED AND RESTATED 2022 STOCK INCENTIVE PLAN NOTICE OF RESTRICTED STOCK GRANT ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its Amended and Restated 2022 Stock Incentive Plan (the “Plan”), hereby grants to the individual listed below (the “Participant”), this grant of shares of restricted Common Stock as set forth below (the |
|
| November 8, 2024 |
ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance •Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net revenues of $52.6 million, an increase of 76.8% year-over-year •Net loss of $(24.2) million and adjusted non-GAAP EBITDA of |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 8, 2024 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commissi |
|
| November 8, 2024 |
ended and Restated 2022 Stock Incentive Plan Sub-Plan for U.K. Employees Exhibit 10.4 ANI PHARMACEUTICALS, INC. (THE “COMPANY”) THE COMPANY’S AMENDED AND RESTATED 2022 STOCK INCENTIVE PLAN (THE “PLAN”) SUB-PLAN FOR U.K. EMPLOYEES (THE “SUB-PLAN”) This Sub-Plan is a sub-plan of the Plan (as amended) and has been created and approved in accordance with the provisions of Section 3.2(e) of the Plan. Terms defined in the Plan shall have the same meanings in this Sub-Plan un |
|
| September 20, 2024 |
2024, by and between ANI Pharmaceuticals, Inc. and Final Form CONFIDENTIAL CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of September 16 (this “Agreement”), is entered into by and between ANI Pharmaceuticals, Inc. |
|
| September 20, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On September 16, 2024 (the “Closing Date”), ANI Pharmaceuticals, Inc. |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 20, 2024 (September 16, 2024) ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of i |
|
| September 16, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 16, 2024 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commis |
|
| September 16, 2024 |
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences FOR IMMEDIATE RELEASE ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences •Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basis •Adds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI’s foothold in strategic therapeutic area of ophthalmology •Antic |
|
| August 13, 2024 |
Exhibit 10.2 CREDIT AGREEMENT among ANI PHARMACEUTICALS, INC., as Lead Borrower, ANIP ACQUISITION COMPANY, as Initial Subsidiary Borrower CERTAIN DOMESTIC SUBSIDIARIES OF THE LEAD BORROWER FROM TIME TO TIME PARTY HERETO, as Guarantors, THE LENDERS PARTY HERETO, and JPMORGAN CHASE BANK, N.A., as Administrative Agent Dated as of August 13, 2024 JPMORGAN CHASE BANK, N.A., REGIONS CAPITAL MARKETS, A D |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 13, 2024 (August 7, 2024) ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorpor |
|
| August 13, 2024 |
Form of Capped Call Transaction Confirmation Exhibit 10.1 [DEALER]1 August [], 2024 To: ANI Pharmaceuticals, Inc. 210 Main Street West Baudette, Minnesota 56623 Attention: Legal Department – General Counsel Re: [Base][Additional] Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [DEALER] (“Dealer”) and ANI Pharmaceutica |
|
| August 13, 2024 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers’ Option to Purchase Additional Notes PRINCETON, N.J., August 13, 2024 (GLOBE NEWSWIRE)—ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the closing of its offering of $316,250,000 aggregate principal amount |
|
| August 13, 2024 |
Exhibit 4.1 ══════════════════════════════════════════════════════ ═══════════════════════════════════════════════════════ ANI Pharmaceuticals, Inc. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee ───────────────────── INDENTURE Dated as of August 13, 2024 ───────────────────── 2.25% Convertible Senior Notes due 2029 ═══════════════════════════════════════════════════════ ════════════ |
|
| August 8, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 7, 2024 (August 7, 2024) ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorpora |
|
| August 8, 2024 |
ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering PRINCETON, N.J., August 7, 2024 (GLOBE NEWSWIRE)—ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the pricing of its offering of $275,000,000 aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offerin |
|
| August 7, 2024 |
ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering PRINCETON, N.J., August 7, 2024 (GLOBE NEWSWIRE)—ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced its intention to offer, subject to market and other conditions, $250,000,000 aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a |
|
| August 7, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 7, 2024 (August 7, 2024) ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorpora |
|
| August 6, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PHARMACEUTICA |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 6, 2024 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| August 6, 2024 |
ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance •Generated record quarterly net revenues of $138.0 million, representing year-over-year growth of 18.4%, and record Rare Disease net revenues of $49.2 million, an increase of 102.4% year-over-year •Delivered adjusted non-GAAP EBITDA of $33.2 million, and adjusted non-GAAP d |
|
| July 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ANI Pharmaceuticals, Inc. |
|
| July 12, 2024 |
As filed with the Securities and Exchange Commission on July 12, 2024 As filed with the Securities and Exchange Commission on July 12, 2024 Registration No. |
|
| July 12, 2024 |
ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan Exhibit 10.1 ANI PHARMACEUTICALS, INC. AMENDED AND RESTATED 2022 STOCK INCENTIVE PLAN (Amended on March 28, 2024) 1.Purpose of Plan. The purpose of the ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan (this “Plan”) is to advance the interests of ANI Pharmaceuticals, Inc. (the “Company”) and its stockholders by enabling the Company and its Subsidiaries to attract and retain |
|
| June 24, 2024 |
FOR IMMEDIATE RELEASE ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences Conference call scheduled for today at 8:30 a. |
|
| June 24, 2024 |
© 2024 ANI Pharmaceuticals, Inc. 1 Acquisition of Alimera Sciences, Inc. June 24, 2024 © 2024 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation contains not only historical information, but also forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the Company’s and Alimera’s |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 24, 2024 (June 21, 2024) ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporati |
|
| June 24, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG: ANI PHARMACEUTICALS, INC. ANIP MERGER SUB INC. and ALIMERA SCIENCES, INC. DATED AS OF JUNE 21, 2024 * The disclosure schedules to this exhibit have been omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K as they contain information that is both not material and of the type that the registrant treats as private or confidential. The regist |
|
| June 24, 2024 |
Exhibit 10.1 ** Certain terms of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K as they are both not material and of the type that the registrant treats as private or confidential. The registrant agrees to supplementally furnish an unredacted copy of this exhibit to the SEC upon its request; however, the registrant may request confidential treatment of such unreda |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 5, 2024 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission F |
|
| June 5, 2024 |
© 2024 ANI Pharmaceuticals, Inc. 1 June 2024 © 2024 ANI Pharmaceuticals, Inc. 2 Disclaimer To the extent any statements made in this presentation deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those relating to the commercialization and po |
|
| May 23, 2024 |
Amended 2022 Stock Plan, Form of Restricted Stock Grant Agreement (Employees) Exhibit 10.3 ANI PHARMACEUTICALS, INC. AMENDED AND RESTATED 2022 STOCK INCENTIVE PLAN NOTICE OF RESTRICTED STOCK GRANT ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its Amended and Restated 2022 Stock Incentive Plan (the “Plan”), hereby grants to the individual listed below (the “Participant”), this grant of shares of restricted Common Stock as set forth below (the |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 21, 2024 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission F |
|
| May 23, 2024 |
Amended 2022 Stock Plan, Form of Restricted Stock Grant Agreement (Directors) Exhibit 10.2 ANI PHARMACEUTICALS, INC. AMENDED AND RESTATED 2022 STOCK INCENTIVE PLAN NOTICE OF RESTRICTED STOCK GRANT ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its Amended and Restated 2022 Stock Incentive Plan (the “Plan”), hereby grants to the individual listed below (the “Participant”), this grant of shares of restricted Common Stock as set forth below (the |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 14, 2024 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission F |
|
| May 14, 2024 |
© 2024 ANI Pharmaceuticals, Inc. 1 Capital One 1st Annual Biotech/Biopharma Disruptors Event May 14, 2024 © 2024 ANI Pharmaceuticals, Inc. 2 Disclaimer To the extent any statements made in this presentation deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are n |
|
| May 10, 2024 |
ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance •Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7%, net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of $0.82 •Delivered record adjusted non-GAAP EBITDA of $37.6 million, a |
|
| May 10, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 10, 2024 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission F |
|
| May 10, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PHARMACEUTIC |
|
| May 10, 2024 |
Exhibit 10.1 [***] Certain information contained in this document has been omitted based on a court order. ASSIGNMENT AND TECHNOLOGY TRANSFER AGREEMENT between BIOSANTE PHARMACEUTICALS, INC. and COLD GENESYS, INC. Dated as of November 15, 2010 ASSIGNMENT AND TECHNOLOGY TRANSFER AGREEMENT This Assignment and Technology Transfer Agreement (“Agreement”) is by and between BioSante Pharmaceuticals, Inc |
|
| April 17, 2024 |
© 2024 ANI Pharmaceuticals, Inc. 1 April 2024 © 2024 ANI Pharmaceuticals, Inc. 2 Disclaimer To the extent any statements made in this presentation deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those relating to the commercialization and p |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 17, 2024 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Additional Materials o Soliciting Material Pursuant to §240. |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to §240. |
|
| March 14, 2024 |
SC 13D/A 1 tm248804d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Amendment No. 8) Under the Securities Exchange Act of 1934 ANI Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00182C103 (CUSIP Number) Robert A. Graham MVP Capital Partners 259 N. Radnor-Chester Road Suite 13 |
|
| March 12, 2024 |
exhibit991-20240312 © 2024 ANI Pharmaceuticals, Inc. 1 March 2024 © 2024 ANI Pharmaceuticals, Inc. 2 Disclaimer To the extent any statements made in this presentation deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those relating to the com |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 12, 2024 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| February 29, 2024 |
Exhibit 10.33 Notice of Termination Agreement of Purchase and Sale - Commercial SELLER, ANI PHARMACEUTICALS CANADA INC. , and BUYER, MASTERCOM INC. BROKERAGES, CRESA TORONTO, BROKERAGE CBRE LIMITED, BROKERAGE (Listing Brokerage) (Co-operating Brokerage) for the Sale of 400 Iroquois Shore Road, Oakville. ON dated the 6th day of November. 2023 We. the Buyer and the Seller in the above noted transact |
|
| February 29, 2024 |
Form of Indemnification Agreement Exhibit 10.34 FORM OF INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT, made and executed this day of , 202, by and between ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and , an individual resident of the State of (the “Indemnitee”). WHEREAS, the Company is aware that, in order to induce highly competent persons to serve the Company as directors or officers or in othe |
|
| February 29, 2024 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance •Generated quarterly net revenues of $131.7 million, representing year-over-year growth of 39.7%, net income to common shareholders of $0.7 million, GAAP diluted earnings per share of $0.04 •Delivered Adjusted non-GAAP EBITDA of $30.2 million, and adj |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-31812 ANI PHARMACEUTICALS, |
|
| February 29, 2024 |
Amendment No. 2024-2 to ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan Exhibit 10.24 AMENDMENT NO. 2024-2 TO ANI PHARMACEUTICALS, INC. AMENDED AND RESTATED 2022 STOCK INCENTIVE PLAN February 5, 2024 WHEREAS, ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), maintains the Company’s Amended and Restated 2022 Stock Incentive Plan (the “Plan”) for the benefit of eligible employees of the Company and subsidiaries, non-employee members of the Board, and ot |
|
| February 29, 2024 |
Amendment to Purchase and Sale Agreement between ANI Pharmaceuticals Canada Inc. and Mastercom Inc. Exhibit 10.32 AMENDMENT TO AGREEMENT OF PURCHASE AND SALE THIS AMENDMENT dated as of November 21, 2023. BETWEEN: ANI PHARMACEUTICALS CANADA INC. (the "Vendor") - and - MASTERCOM INC. (the "Purchaser") WHEREAS: A.the Vendor and the Purchaser entered into an agreement of purchase and sale dated as of November 6, 2023, and which was fully executed by the parties on November 7, 2023 (the “Purchase Agr |
|
| February 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 29, 2024 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commiss |
|
| February 29, 2024 |
Exhibit 21 ANI PHARMACEUTICALS, INC. The following is a list of subsidiaries of ANI Pharmaceuticals, Inc., omitting subsidiaries which, considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary, as of December 31, 2023: Name Jurisdiction of Incorporation or Organization ANIP Acquisition Company Delaware ANI Pharmaceuticals Canada Inc. Canada Novitium Pharma, |
|
| February 29, 2024 |
Purchase and Sale Agreement between ANI Pharmaceuticals Canada Inc. and Mastercom Inc. Exhibit 10.31 THIS AGREEMENT OF PURCHASE AND SALE made this 23 day of November 2023 BETWEEN: ANI PHARMACEUTICALS CANADA INC. (the “Vendor”) OF THE FIRST PART - and - MASTERCOM INC. (the “Purchaser”) OF THE SECOND PART WHEREAS the Vendor is the owner of the Property and has agreed to sell, transfer, assign, set over and convey the Property to the Purchaser and the Purchaser has agreed to purchase, |
|
| February 29, 2024 |
ANI Pharmaceuticals, Inc. Amended and Restated Clawback Policy Exhibit 97.1 ANI PHARMACEUTICALS, INC. AMENDED AND RESTATED CLAWBACK POLICY I.Purpose. The Board of Directors (“Board”) of ANI Pharmaceuticals, Inc. (the “Company”) based upon the recommendation of its Compensation Committee (the “Committee”), has adopted this Compensation Recoupment Policy (this “Policy”) in order to implement a mandatory clawback policy in the event of a Restatement in complianc |
|
| February 23, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 16, 2024 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commiss |
|
| February 23, 2024 |
Agreement of Purchase and Sale between ANI Pharmaceuticals Canada, Inc. and 1540700 Ontario Limited Exhibit 10.1 Dentons Draft – September 19, 2023 THIS AGREEMENT OF PURCHASE AND SALE made this 15th day of February 2024 BETWEEN: ANI PHARMACEUTICALS CANADA INC. (the “Vendor”) OF THE FIRST PART - and - 1540700 ONTARIO LIMITED (the “Purchaser”) OF THE SECOND PART WHEREAS the Vendor is the owner of the Purchased Assets and has agreed to sell, transfer, assign, set over and convey the Purchased Asset |
|
| February 13, 2024 |
ANIP / ANI Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv0292-anipharmaceuticalsinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: ANI Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 00182C103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule purs |
|
| February 12, 2024 |
ANIP / ANI Pharmaceuticals, Inc. / Rubric Capital Management LP - SC 13G Passive Investment SC 13G 1 tm245464d1sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ANI Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00182C103 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 8, 2024 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commissi |
|
| February 8, 2024 |
anipharmaceuticalsdeckfe February 2024 © 2024 ANI Pharmaceuticals, Inc. 1 Disclaimer © 2024 ANI Pharmaceuticals, Inc. 2 This presentation by ANI Pharmaceuticals, Inc (“ANI” or the “Company”) contains forward-looking statements, including information about management's view of the Company’s future expectations, plans and prospects, as well as other forward-looking statements. Any statements made in |
|
| January 17, 2024 |
ANIP / ANI Pharmaceuticals, Inc. / Esjay LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) ANI Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00182C103 (CUSIP Number) Esjay LLC 16732 Strasbourg Lane Delray Beach, Florida 33446 845-652-0377 (Name, Address and Telephone Number of Pe |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commissio |
|
| January 8, 2024 |
exhibit991investordeckja © 2023 ANI Pharmaceuticals, Inc. 1 January 2024 © 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc (“ANI” or the “Company”) contains forward-looking statements, including information about management's view of the Company’s future expectations, plans and prospects, as well as other forward-looking statements. Any statements made in |
|
| December 18, 2023 |
SC 13D/A 1 tm2333161d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Amendment No. 7) Under the Securities Exchange Act of 1934 ANI Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00182C103 (CUSIP Number) Robert A. Graham MVP Capital Partners 259 N. Radnor-Chester Road Suite 1 |
|
| December 5, 2023 |
ANIP / ANI Pharmaceuticals Inc / Esjay LLC - SC 13D/A Activist Investment SC 13D/A 1 tm2332094d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) ANI Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00182C103 (CUSIP Number) Esjay LLC 16732 Strasbourg Lane Delray Beach, Florida 33446 845-652-0377 |
|
| November 15, 2023 |
© 2023 ANI Pharmaceuticals, Inc. 1 Jefferies London Healthcare Conference November 2023 © 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc (“ANI” or the “Company”) contains forward-looking statements, including information about management's view of the Company’s future expectations, plans and prospects, as well as other forward-looking statements. Any stat |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 15, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commiss |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 8, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commissi |
|
| November 8, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance Third Quarter 2023 Financial Results - Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3%; net income available to common shareholders of $9.5 million and diluted GAAP income per share of $0.45 - - Record quarterly a |
|
| November 8, 2023 |
Exhibit 10.1 EXECUTION VERSION AMENDMENT NO. 1 TO CREDIT AGREEMENT This AMENDMENT NO. 1 TO CREDIT AGREEMENT, dated as of July 3, 2023 (this “Amendment”), is made by and among ANI PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”), and TRUIST BANK, as Administrative Agent (in such capacity, the “Administrative Agent”). Capitalized terms used but not defined herein have the respective me |
|
| November 8, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PHARMACE |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 2, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commissio |
|
| October 2, 2023 |
For Immediate Release ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares Cortrophin Gel is the only FDA-approved purified corticotropin (ACTH) indicated for the treatment of appropriate patients with acute gouty arthritis flares New 1-mL |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 25, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commis |
|
| September 25, 2023 |
© 2023 ANI Pharmaceuticals, Inc. 1 Investor Presentation September 2023 © 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc (“ANI” or the “Company”) contains forward-looking statements, including information about management's view of the Company’s future expectations, plans and prospects, as well as other forward-looking statements. Any statements made in t |
|
| September 12, 2023 |
© 2023 ANI Pharmaceuticals, Inc. 1 Investor Presentation September 2023 © 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc (“ANI” or the “Company”) contains forward-looking statements, including information about management's view of the Company’s future expectations, plans and prospects, as well as other forward-looking statements. Any statements made in t |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 11, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commis |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 7, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commiss |
|
| September 7, 2023 |
© 2023 ANI Pharmaceuticals, Inc. 1 Investor Presentation September 2023 © 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc (“ANI” or the “Company”) contains forward-looking statements, including information about management's view of the Company’s future expectations, plans and prospects, as well as other forward-looking statements. Any statements made in t |
|
| August 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 30, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commissio |
|
| August 30, 2023 |
Exhibit 99.1 © 2023 ANI Pharmaceuticals, Inc. 1 © 2023 ANI Pharmaceuticals, Inc. 1 Investor Presentation August 2023 © 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc (“ANI” or the “Company”) contains forward - looking statements, including informatio n about management's view of the Company’s future expectations, plans and prospects, as well as other forw |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 21, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commissio |
|
| August 23, 2023 |
Exhibit 99.1 ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors - Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience - Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy - BAUDETTE, Minn.— August 23, 2023 (Globe Newswire) - ANI Pharmaceut |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Amendment No. |
|
| August 9, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance Second Quarter 2023 Financial Results - Record quarterly net revenues of $116.5 million, representing year-over-year growth of 57.8%; net income available to common shareholders of $5.8 million and diluted GAAP income per share of $0.29 - - Record quarterly |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 9, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI PH |
|
| June 23, 2023 |
Exhibit 10.1 AMENDMENT NO. 2023-1 TO ANI PHARMACEUTICALS, INC. AMENDED AND RESTATED 2022 STOCK INCENTIVE PLAN Effective May 23, 2023 WHEREAS, ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), maintains the Company’s Amended and Restated 2022 Stock Incentive Plan (the “Plan”) for the benefit of eligible employees of the Company and subsidiaries, non-employee members of the Board, a |
|
| June 23, 2023 |
As filed with the Securities and Exchange Commission on June 23, 2023 As filed with the Securities and Exchange Commission on June 23, 2023 Registration No. |
|
| June 23, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ANI Pharmaceuticals, Inc. |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 9, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission F |
|
| June 9, 2023 |
Exhibit 99.1 © 2023 ANI Pharmaceuticals, Inc. 1 © 2023 ANI Pharmaceuticals, Inc. 1 Jefferies Healthcare Conference June 2023 © 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc (“ANI” or the “Company”) contains forward - looking statements, including informatio n about management's view of the Company’s future expectations, plans and prospects, as well as ot |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| May 16, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 16, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission F |
|
| May 16, 2023 |
Exhibit 99.1 ANI PHARMACEUTICALS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK INCLUDING FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES BAUDETTE, Minn.— (BUSINESS WIRE) – May 16, 2023 — ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) today announced the closing of its previously announced underwritten public offering. A total of 2,183,545 shares of its |
|
| May 12, 2023 |
ANI Pharmaceuticals, Inc. 1,898,735 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-239771 Prospectus Supplement (To prospectus dated July 17, 2020) ANI Pharmaceuticals, Inc. 1,898,735 Shares of Common Stock We are offering 1,898,735 shares of our common stock, par value $0.0001 per share (the “common stock”). Our common stock is listed on the Nasdaq Global Market under the symbol “ANIP.” On May 10, 2023, t |
|
| May 12, 2023 |
EX-1.1 2 tm2315239d4ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 1,898,735 Shares of Common Stock ANI PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT May 11, 2023 Guggenheim Securities, LLC As Representative of the several Underwriters named in Schedule I attached hereto c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Ladies and Gentlemen: ANI Pharmaceuticals, Inc., a corporation orga |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 11, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission F |
|
| May 12, 2023 |
ANI PHARMACEUTICALS ANNOUNCES PRICING OF $75 MILLION PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 ANI PHARMACEUTICALS ANNOUNCES PRICING OF $75 MILLION PUBLIC OFFERING OF COMMON STOCK BAUDETTE, Minn.- (BUSINESS WIRE) – May 12, 2023 - ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the "Company") today announced the pricing of its previously announced underwritten public offering of 1,898,735 shares of its common stock at a public offering price of $39.50 per share. The gross pro |
|
| May 12, 2023 |
Exhibit 107 The prospectus to which this Exhibit 107 is attached is a final prospectus for the related offering. The maximum aggregate offering price for such offering is $86,250,027.50 |
|
| May 11, 2023 |
ANI PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 ANI PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK BAUDETTE, Minn.- (BUSINESS WIRE) – May 11, 2023 - ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI”) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by ANI. The offering is subject to market c |
|
| May 11, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 11, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission F |
|
| May 11, 2023 |
Subject to Completion, Dated May 11, 2023 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI P |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 8, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 7, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 8, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Record First Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance First Quarter 2023 Financial Results - Record quarterly net revenues of $106.8 million, representing year-over-year growth of 65.6%; 2023 first-quarter net income available to common shareholders of $1.0 million and diluted GAAP income per share of $0.06 - - |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material Pursuant to §240. |
|
| April 11, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material Pursuant to §240. |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 10, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 9, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-31812 ANI PHARMA |
|
| March 9, 2023 |
Exhibit 21 ANI PHARMACUTICALS, INC. The following is a list of subsidiaries of ANI Pharmaceuticals, Inc., omitting subsidiaries which, considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary, as of December 31, 2022: Name Jurisdiction of Incorporation or Organization ANIP Acquisition Company Delaware ANI Pharmaceuticals Canada Inc. Canada Novitium Pharma, |
|
| March 9, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Record Fourth Quarter Financial Results and Achieves Full Year 2022 Revenue Milestone; Initiates 2023 Guidance Fourth Quarter and Full Year 2022 Financial Results - Q4 net revenues of $94.2 million, net loss available to common shareholders of $(4.7) million and diluted GAAP loss per share of $(0.28) – - Q4 Adjusted non-GAAP EBITDA of |
|
| March 6, 2023 |
Second Amended and Restated Bylaws of ANI Pharmaceuticals, Inc. Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF ANI PHARMACEUTICALS, INC. ARTICLE I. OFFICES Section 1. Registered Office. The registered office of ANI Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Corporation”) shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 2. Other Offices. The Corporation may also have office |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): February 28, 2023 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commiss |
|
| January 27, 2023 |
ANI Pharmaceuticals, Inc. 210 Main Street West Baudette, Minnesota 56623 January 27, 2023 ANI Pharmaceuticals, Inc. 210 Main Street West Baudette, Minnesota 56623 January 27, 2023 Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: ANI Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended December 31, 2021 Filed March 15, 2022 Form 8-K furnished August 8, 2022 File No. 001-31812 Ladies an |
|
| January 6, 2023 |
ANI Pharmaceuticals, Inc. 210 Main Street West Baudette, Minnesota 56623 January 6, 2023 CORRESP 1 filename1.htm ANI Pharmaceuticals, Inc. 210 Main Street West Baudette, Minnesota 56623 January 6, 2023 Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: ANI Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended December 31, 2021 Filed March 15, 2022 Form 8-K furnished August 8, 2022 File |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Amendment No. |
|
| December 5, 2022 |
ANI Pharmaceuticals, Inc. 210 Main Street West Baudette, Minnesota 56623 December 5, 2022 ANI Pharmaceuticals, Inc. 210 Main Street West Baudette, Minnesota 56623 December 5, 2022 Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: ANI Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended December 31, 2021 Filed March 15, 2022 Form 8-K furnished August 8, 2022 File No. 001-31812 Ladies an |
|
| November 9, 2022 |
Employment Agreement between Krista Davis and ANI Pharmaceuticals, Inc. dated July 14, 2022. ? Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT ? EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) between ANI Pharmaceuticals, Inc. (the ?Company?) and Krista Davis (?Executive?) dated as of July 14, 2022. Each of the Company and Executive are sometimes referred to herein individually as a ?Party? and together as the ?Parties.? ? WHEREAS, the Company wishes to employ Executive, and Executive wishe |
|
| November 9, 2022 |
ANI Pharmaceuticals, Inc. November 9, 2022 Exhibit 99.1 ANI Pharmaceuticals, Inc. November 9, 2022 Corporate Speakers ? Judy DiClemente; ANI Pharmaceuticals, Inc.; Investor Relations ? Nikhil Lalwani; ANI Pharmaceuticals, Inc.; President and Chief Executive Officer ? Steven Carey; ANI Pharmaceuticals, Inc.; Chief Financial Officer ? Christopher Mutz; ANI Pharmaceuticals, Inc.; Head of Rare Disease of ANI Participants ? Elliot Wilbur; Raymo |
|
| November 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commiss |
|
| November 9, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues Third Quarter 2022 Results: - Net revenues of $83.8 million, net loss available to common shareholders of $(9.0) million and diluted GAAP loss per share of $(0.55) ? - Adjusted non-GAAP EBITDA of $19.6 million and adjusted non-GAAP diluted earnings per share of $0.64 - - |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commiss |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 8, 2022 |
Employment Agreement between Meredith Cook and the Company, dated June 21, 2022. ? ? Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT ? EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) between ANI Pharmaceuticals, Inc. (the ?Company?) and Meredith Cook (?Executive?) dated as of June 21, 2022. Each of the Company and Executive are sometimes referred to herein individually as a ?Party? and together as the ?Parties.? ? WHEREAS, the Company wishes to employ Executive, and Executive wi |
|
| August 8, 2022 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No.1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorpor |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commissio |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 8, 2022 |
Exhibit 99.1 ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin? Gel Second Quarter 2022 Results: - Net revenues of $73.9 million, net loss available to common shareholders of $(15.3) million and diluted GAAP loss per share of $(0.94) ? - Lead Rare Disease asset, Purified Cortrophin? |
|
| June 2, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition - Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023 - - Action part of ongoing efforts to drive cost-competitiveness and deliver sustainable growth for generics business - - Preliminary estimate of |
|
| June 2, 2022 |
Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2022 |
EX-99.1 2 tm2214896d199-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million - First quarter net revenues of $64.5 million, net loss of $(20.1) million and diluted GAAP loss per share of $(1.27) - - Fir |
|
| May 10, 2022 |
Asset Purchase Agreement between Cranford Pharmaceuticals, LLC and ANI Pharmaceuticals, Inc. (2) Exhibit 10.1 ? EXECUTION COPY ? CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***].? ? ASSET PURCHASE AGREEMENT ? between ? CRANFORD PHARMACEUTICALS, LLC ? and ? ANI PHARMACEUTICALS, INC. ? DATED AS OF FEBRUARY 23, 2017 ? TABLE |
|
| May 10, 2022 |
Asset Purchase Agreement between Holmdel Pharmaceuticals, LP and ANI Pharmaceuticals, Inc. (2) Exhibit 10.2 ? EXECUTION COPY ? CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***].? ? ASSET PURCHASE AGREEMENT ? between ? HOLMDEL PHARMACEUTICALS, LP ? and ? ANI PHARMACEUTICALS, INC. ? DATED AS OF FEBRUARY 23, 2017 ? TABLE OF |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2022 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commissio |
|
| April 27, 2022 |
As filed with the Securities and Exchange Commission on April 27, 2022 As filed with the Securities and Exchange Commission on April 27, 2022 Registration No. |
|
| April 27, 2022 |
EX-FILING FEES 4 tm2213329d1ex-fillingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ANI Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 25, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Proxy Statement ? ? Definitive Additional Materials ? ? Soliciting Material Pursuant to ?240. |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2022 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commissio |
|
| March 23, 2022 |
Exhibit 99.1 ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors - Dr. Tannenbaum?s successful track record in driving commercial excellence to contribute as Company executes Purified Cortrophin GelTM launch - BAUDETTE, Minn., March 22, 2022 ? ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced the addition |
|
| March 15, 2022 |
Exhibit 10.25 ? Certain information has been excluded from this agreement (indicated by ?[***]?) because such information is both not material and the type that the registrant treats as private or confidential. ? MASTER PRODUCT DEVELOPMENT AND COLLABORATION AGREEMENT ? BY AND AMONG ? RICONPHARMA LLC ? AND ? ANIP ACQUISITION COMPANY d/b/a ANI PHARMACEUTICALS, INC. ? JULY 2011 ? This MASTER PRODUCT |
|
| March 15, 2022 |
Exhibit 21 ? ANI PHARMACUTICALS, INC. ? The following is a list of subsidiaries of ANI Pharmaceuticals, Inc., omitting subsidiaries which, considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary, as of December 31, 2021: ? Name Jurisdiction of Incorporation or Organization ANIP Acquisition Company Delaware ANI Pharmaceuticals Canada Inc. Canada Novitium Ph |
|
| March 15, 2022 |
? Exhibit 10.24 ? Certain information has been excluded from this agreement (indicated by ?[***]?) because such information is both not material and the type that the registrant treats as private or confidential. ? ? SUBLICENSE AGREEMENT ? This Sublicense Agreement (the ?Agreement?) is entered into as of the 30th day of October, 2009 by and between ANIP ACQUISITION COMPANY, d/b/a ANI PHARMACEUTICA |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 15, 2022 |
Employment Agreement between Ori Gutwerg and the Company, dated January 1 Exhibit 10.27 Execution Version EXECUTIVE EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) between ANI Pharmaceuticals, Inc. (the ?Company?) and Ori Gutwerg (?Executive?) dated as of January 15, 2021. Each of the Company and Executive are sometimes referred to herein individually as a ?Party? and together as the ?Parties.? WHEREAS, the Company wishes to employ Executive, and |
|
| March 15, 2022 |
Employment Agreement between Chad Gassert and the Company, dated March 8, 2021. Exhibit 10.28 Execution Version EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) between ANI Pharmaceuticals, Inc. (the ?Company?) and Chad Gassert (?Executive?) dated as of March 8, 2021. Each of the Company and Executive are sometimes referred to herein individually as a ?Party? and together as the ?Parties.? WHEREAS, in connection with the transactions conte |
|
| March 15, 2022 |
EX-99.1 2 tm228896d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth - Fourth quarter net revenues of $60.9 million; net loss of $24.1 million and diluted loss per share of $1.72 - - Fourth quarter adjusted non-GAAP EBITDA of $16.2 million and adjusted non-GAAP diluted earnings per sha |
|
| March 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commissio |
|
| March 15, 2022 |
Employment Agreement between and Christopher Mutz and the Company, dated February 10, 2021. Exhibit 10.26 Execution Draft EXECUTIVE EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) between ANI Pharmaceuticals, Inc. (the ?Company?) and Christopher Mutz (?Executive?) dated as of February 10, 2021. Each of the Company and Executive are sometimes referred to herein individually as a ?Party? and together as the ?Parties.? WHEREAS, the Company wishes to employ Executive, |
|
| March 2, 2022 |
ANIP / ANI Pharmaceuticals Inc / Esjay LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ANI Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00182C103 (CUSIP Number) Esjay LLC 16732 Strasbourg Lane Delray Beach, Florida 33446 845-652-0377 (Name, Address and Telephone Number of Person Authorized to |
|
| February 28, 2022 |
ANI Pharmaceuticals, Inc. Executive Incentive Bonus Plan Exhibit 10.1 ANI PHARMACEUTICALS, INC. EXECUTIVE INCENTIVE BONUS PLAN 1. PURPOSE The purpose of the ANI Pharmaceuticals, Inc. Executive Incentive Bonus Plan (as amended from time to time, the ?Plan?) is to motivate and reward eligible employees for their contributions toward the achievement of certain Performance Goals (as defined below) by ANI Pharmaceuticals, Inc. (together with any of its Affil |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commis |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commis |
|
| January 24, 2022 |
Exhibit 99.1 ANI Pharmaceuticals, Inc. 210 Main Street West Baudette, MN 56623 https://www.anipharmaceuticals.com ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin? Gel (Repository Corticotropin Injection USP) for Multiple Chronic Autoimmune Disorders BAUDETTE, Minn., January 24, 2022 ? ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced the U.S |
|
| January 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2022 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commiss |
|
| January 19, 2022 |
TABLE OF CONTENTS ?Filed pursuant to Rule 424(b)(3) ?Registration Statement No: 333-261731? PROSPECTUS 3,069,555 Shares Common Stock This prospectus relates to the resale or other disposition from time to time of up to 3,069,555 shares of our common stock held by the selling stockholders named herein (the ?selling stockholders?), including their permitted transferees, assignees, pledgees, donees or other successors in interest. |
|
| January 13, 2022 |
ANI Pharmaceuticals, Inc. 210 Main Street West Baudette, Minnesota 56623 January 13, 2022 ANI Pharmaceuticals, Inc. 210 Main Street West Baudette, Minnesota 56623 January 13, 2022 Via Edgar Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Michael Davis Re: ANI Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-261731) Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities |
|
| December 17, 2021 |
As filed with the Securities and Exchange Commission on December 17, 2021 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 17, 2021 Registration No. |
|
| November 26, 2021 |
Exhibit 10.1 EXECUTION VERSION Published Deal CUSIP Number:03524QAD5 Published Term Loan CUSIP Number:03524QAE3 Published Revolver CUSIP Number:03524QAF0 CREDIT AGREEMENT among ANI PHARMACEUTICALS, INC., as Borrower, CERTAIN DOMESTIC SUBSIDIARIES OF THE BORROWER FROM TIME TO TIME PARTY HERETO, as Guarantors, THE LENDERS PARTY HERETO, and TRUIST BANK, as Administrative Agent Dated as of November 19 |
|
| November 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2021 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commis |
|
| November 26, 2021 |
EX-3.1 2 tm2133555d1ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 ANI PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Nikhil Lalwani, does hereby certify that: 1. I am the President and Chief Executive Officer of ANI Pharmaceuticals, Inc., a Delaware |
|
| November 26, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses - Combined company creates generics growth engine with technical capabilities to bring complex, high-value products to market in efficient and cost effect manner - - Proven track record with largest number of Competitive |
|
| November 26, 2021 |
Exhibit 10.3 Execution Version EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) between ANI Pharmaceuticals, Inc. (the ?Company?) and Muthusamy Shanmugam (?Executive?) dated as of March 8, 2021. Each of the Company and Executive are sometimes referred to herein individually as a ?Party? and together as the ?Parties.? WHEREAS, in connection with the transactions |
|
| November 26, 2021 |
Exhibit 99.5 Unaudited Pro Forma Condensed Combined Financial Information The following unaudited pro forma combined financial information is presented to illustrate the estimated effect of the Merger Agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities for $185.4 million, including $89.5 |
|
| November 26, 2021 |
Registration Rights Schedule to the Merger Agreement, effective as of November 19, 2021 Exhibit 4.1 Exhibit Q ? Final Form SCHEDULE TO MERGER AGREEMENT REGISTRATION RIGHTS 1. GENERAL All capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Merger Agreement. As used in this Schedule, the following terms shall have the following meanings: (a) ?Holders? means the Persons listed on the Exhibit A to this Schedule (individually, a ?H |
|
| November 5, 2021 |
TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration Statement No. 333-239771? PROSPECTUS SUPPLEMENT (To Prospectus dated July 17, 2020) 1,500,000 Shares Common Stock We are offering 1,500,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol ?ANIP.? On November 3, 2021, the last reported sale price of shares of our common stock on th |
|
| November 4, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commiss |
|
| November 4, 2021 |
Exhibit 1.1 Execution Version 1,500,000 Shares of Common Stock ANI PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT November 3, 2021 Guggenheim Securities, LLC As Representative of the several Underwriters named in Schedule I attached hereto c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Ladies and Gentlemen: ANI Pharmaceuticals, Inc., a corporation organized and existing u |
|
| November 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commiss |
|
| November 3, 2021 |
SUBJECT TO COMPLETION, DATED NOVEMBER 3, 2021 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| November 3, 2021 |
ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock Baudette, Minnesota, November 3, 2021?ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (?ANI?) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by ANI. The offering is subject to market conditi |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 1, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Third Quarter 2021 Results - Third quarter 2021 net revenues of $52.1 million; net loss of $4.4 million and diluted loss per share of ($0.37) - - Third quarter adjusted non-GAAP EBITDA of $16.6 million and adjusted non-GAAP diluted earnings per share of $1.01 - - FDA approves supplemental new drug application for Purified Cortrophin? G |
|
| November 1, 2021 |
Form of ANI Pharmaceuticals, Inc. Inducement Stock Option Award Agreement. Exhibit 99.1 ANI PHARMACEUTICALS, INC. NON-PLAN INDUCEMENT STOCK OPTION NOTICE OF STOCK OPTION GRANT Participant: [INSERT NAME] Participant has been granted an Option to purchase Common Stock (?Shares?) of ANI Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), subject to the terms and conditions of this Notice of Stock Option Grant (the ?Notice of Grant?) and the attached Stock Option |
|
| November 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commiss |
|
| November 1, 2021 |
As filed with the Securities and Exchange Commission on November 1, 2021 As filed with the Securities and Exchange Commission on November 1, 2021 Registration No. |
|
| August 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2021 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commissio |
|
| August 6, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Second Quarter 2021 Results - Second quarter 2021 net revenues of $48.6 million; net loss of $14.1 million and diluted loss per share of ($1.17) - - Second quarter adjusted non-GAAP EBITDA of $13.1 million and adjusted non-GAAP diluted earnings per share of $0.67 - - Refiled supplemental new drug application (?sNDA?) for Cortrophin Gel |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 4, 2021 |
Exhibit 99.1 ? 2021 ANI Pharmaceuticals, Inc. 1 ? 2021 ANI Pharmaceuticals, Inc. 1 Jefferies Healthcare Conference June 2021 Jefferies Healthcare Conference ? 2021 ANI Pharmaceuticals, Inc. 2 Disclaimer Cautionary Note Regarding Forward - Looking Statements This presentation contemplates the acquisition by ANI Pharmaceuticals, Inc (?ANI? or the ?Company?) of Novitium Pharma, LLC (? Novitium ?) and |
|
| June 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| May 7, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports First Quarter 2021 Results - First quarter 2021 net revenues of $54.5 million; net income of $0.1 million and diluted earnings per share of $0.01 - - First quarter adjusted non-GAAP EBITDA of $18.9 million and adjusted non-GAAP diluted earnings per share of $1.04 - - Cortrophin? Gel sNDA re-filing on track for Q2 2021 submission - - St |
|
| May 7, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 7, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2021 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission F |
|
| May 7, 2021 |
DEFA14A 1 tm2115505d2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary proxy statement. ¨ Confidential, for use of the Commission only (as permitted by |
|
| April 29, 2021 |
Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 29, 2021; TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary proxy statement. ? ? Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) |
|
| April 19, 2021 |
PRE 14A 1 tm212613-1pre14a.htm PRE 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary proxy statement. ☐ Confidential, for use of the Commission only ( |
|
| April 6, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2021 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31812 58-2301143 (State or other jurisdiction of incorporation) (Commission |
|
| April 6, 2021 |
ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs - Accretive transaction in line with growth strategy laid out for Branded Products business - Baudette, Minnesota (April 6, 2021) ? ANI Pharmaceuticals, Inc. (?ANI?) (NASDAQ:ANIP) today announced that it has acquired the new drug applications (?NDAs?) for OXISTAT? Lotio |
|
| March 11, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 11, 2021 |
? ?? Exhibit 10.20 ANI PHARMACEUTICALS, INC. SIXTH AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN NOTICE OF STOCK OPTION GRANT Participant: You have been granted an Option to purchase Common Stock (?Shares?) of ANI Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), subject to the terms and conditions of this Notice of Stock Option Grant (the ?Notice of Grant?), the ANI Pharmaceuticals, |
|
| March 11, 2021 |
Exhibit 21 ? ANI PHARMACUTICALS, INC. ? The following is a list of subsidiaries of ANI Pharmaceuticals, Inc., omitting subsidiaries which, considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary, as of December 31, 2020: ? Name Jurisdiction of Incorporation or Organization ANIP Acquisition Company Delaware ANI Pharmaceuticals Canada Inc. Canada ? |
